TORONTO, ON - (NewMediaWire) - November 3, 2015 - In parallel with Easton's Focus on Women's Health, Easton Pharmaceuticals (OTC PINK: EAPH) is pleased to announce it can commence the marketing and sales of approved products for most of the Latin American markets. Easton further announces the attendance of the 66th Mexican Congress of Obstetrics & Gynecology in Acapulco being held between November 2 to November 5th.
AL-Sense Amniotic Fluid Diagnostic Test Approval
Easton Pharmaceuticals and its partner BMV have the rights to the approved amniotic fluid leak test, and are in the process of final packaging for the Latin American market under the EvaPro brand. Sales could begin immediately once commercial alliances have been established in the region. These exclusive licensing rights were jointly purchased by Easton and BMV Medica from Israel-based Common Sense Inc. on a 50/50 profit sharing agreement which encompasses the countries in Central and South America except Brazil. Final approval in Mexico is expected by the end of 2015 or early 2016. The AL-Sense Amniotic Fluid Diagnostic Leak Test is a patented women's diagnostic product that is currently being sold in the United Kingdom, and has European Approval. It serves a huge market, and the birth rate in Latin America is three times the birth rate in North America and most of Europe. The target market for BMV/Easton has a population exceeding 400 million people, half of which are woman. Sales in Latin America for pharmaceutical and diagnostic products are expected to grow exponentially compared to North America and Europe as a result of a much higher birthrate in the region.
VS-Sense Diagnostic Test Approval
In addition to the approved products that can be immediately marketed and sold is the approval of the VS-Sense product for most Latin American countries except for Argentina and Chile where Easton can immediately start to market and sell the product due to the fact it has US, Canadian and EU approvals.
GynoFit Lactic Acid Gel Treatment For Bacterial Vaginosis (BV) in Mexico
Already approved in Mexico by the Swiss manufacturer who used a regulatory consultant to approve the product, Easton / BMV has an understanding in place including pricing from the manufacturer, pending the signing of a final contract and transfer of license to BMV. This product is expected to become a big selling product due to the fact it can treat the BV successfully without the use of harsh drugs.
The two approved products can be sold almost immediately in these countries pending final design and packaging with the GynoFit Lactic Acid Gel Treatment being sold immediately following the execution of the signed contract. BMV/Easton has commenced discussions for distribution of the products with accredited distribution partners and is in discussions for another approved diagnostic product for Mexico and Latin America.
66th Annual Obstetrics & Gynecology Congress Acapulco Nov. 02 to Nov. 05
Distribution as well as an introduction to all the approved products will be showcased at this well-attended conference, which is being held this week between November 2 and November 5th and is being attended by Easton and its partner BMV Medica. Dr. Jose Tiran Saucedo, who is a consultant to BMV/Easton Pharmaceuticals, is lecturing on several topics at the conference.
Dr. Jose Tiran Saucedo
Easton Pharmaceuticals previously announced the appointment of Dr. Jose Tiran Saucedo as the Founding Member of Easton Pharma's Medical/ Scientific Advisory Board. In this capacity, Dr. Tiran will advise Easton Pharmaceuticals and partners in planning the Latin American launches of its suite of patented, exclusive women's health products over the coming months.
Dr. Tiran stated, "I am very excited to be part of the program for these soon-to-be-launched women's health and treatment products in the hope of providing to Latin American women the same choices they have in the US and Europe. We have a huge unmet medical need in Latin America for these kinds of alternative diagnostic and treatment products. The vaginal discharge diagnostic test will facilitate a woman's ability to determine the causative agent; the natural lactic acid treatment gel will provide a new, non-toxic treatment option, and put Latin American women on a par with North American and European women. The professional version of this diagnostic test will also enable the gynecologist to increase the accuracy in the differential diagnosis of vaginal discharge, right in the gynecologist's office, something currently lacking in Latin America. The natural lactic acid gel treatment expected to launch in parallel with the diagnostic will be offered to women who test positive for bacterial infection and is a significant treatment option advance since it could obviate the need for potential use of antibiotics and further presence of bacterial resistance, so this is a promising and exciting development for the future of women's health."
Dr. Tiran further commented, "The amniotic fluid leak test will allow late-pregnancy women to have at their disposal a high-specificity/accuracy test at a fractional cost to other options on the market, with a very favorable ease-of-use component, thus contributing to an increase in the quality of perinatal care in Latin America. All these are new advances coming to Latin America, which I believe will catch on very quickly in both the community and the professional arenas."
Dr. Jose Tiran is a Thought Leader (KOL - Key Opinion Leader) in Gynecological Infectious Diseases, and is a Fellow of the American College of Obstetricians and Gynecologists. He has been a strong advocate over the years in women's health worldwide. Also, Dr. Tiran has published numerous peer-reviewed papers on the subject, and is also board certified in Mexico, a member of multiple health societies, and holds numerous other prestigious positions in the field of Women's Health. Dr. Tiran is also well versed in other aspects of women's health such as sexually transmitted diseases, female sexual health, contraception, vaccines and gynecology and women's health and wellbeing.
Easton has made demands for the return of its retainer from its Canadian based Auditor, Ateet Kapadia due to the fact he no longer possesses a PAOCB certification as per agreement, which is required by the SEC for US listed public companies. Requests have been made for the return of the funds as Mr. Kapadia has not regained his PAOCB certification as per demands made and assurances given. Easton is now moving towards engaging a US based auditor.
In other news, Easton Pharmaceuticals will be soon disclosing positive updates on its Canadian Medical Marijuana initiatives following the newly elected Federal Liberal government which has disclosed it will be drastically changing the federal stance on medical marijuana in Canada.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries such as medical marijuana. The Company previously developed and owned an FDA approved wound-healing drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton has entered into a 50 / 50 revenue sharing agreement towards being the exclusive distributor in Mexico and Latin America for patented women's diagnostic products and two generic cancer products. Easton has also made additional investments into AMFIL Technologies, a company who own rights to a product called the groZONE anti-microbial airflow system and hold an exclusive option to purchase up to 49% in a (MMPR) medical marijuana grow-op business post granting of license from Health Canada in Ontario, which has received a letter to build from Health Canada. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs and Cannabidiol extracts.
For More Information Visit:
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.